HJ Research delivers in-depth insights on the global Clinical Oncology Next Generation Sequencing (NGS) market in its upcoming report titled, Global Clinical Oncology Next Generation Sequencing (NGS) Market Report 2018-2029. According to this study, the global Clinical Oncology Next Generation Sequencing (NGS) market is estimated to be valued at XX Million US$ in 2023 and is projected to reach XX Million US$ by 2029, expanding at a CAGR of XX% during the forecast period. The report on Clinical Oncology Next Generation Sequencing (NGS) market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, industrial chain, etc.
This report studies the Clinical Oncology Next Generation Sequencing (NGS) market status and outlook of global and major regions, from angles of players, countries, product types and end industries, this report analyzes the top players in global Clinical Oncology Next Generation Sequencing (NGS) industry, and splits by product type and applications/end industries. This report also includes the impact of COVID-19 on the Clinical Oncology Next Generation Sequencing (NGS) industry.
Global Clinical Oncology Next Generation Sequencing (NGS) market: competitive landscape analysis
This report contains the major manufacturers analysis of the global Clinical Oncology Next Generation Sequencing (NGS) industry. By understanding the operations of these manufacturers (revenue and gross margin from 2018 to 2023), the reader can understand the strategies and collaborations that the manufacturers are focusing on combat competition in the market.
Global Clinical Oncology Next Generation Sequencing (NGS) market: types and end industries analysis
The research report includes specific segments such as end industries and product types of Clinical Oncology Next Generation Sequencing (NGS). The report provides market size for each type and end industry from 2018 to 2023. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Global Clinical Oncology Next Generation Sequencing (NGS) market: regional analysis
Geographically, this report is segmented into several key countries, with market size, growth rate of Clinical Oncology Next Generation Sequencing (NGS) in these countries from 2018 to 2023, which covering United States, Canada, Germany, France, UK, Italy, Russia, Spain, Netherlands, China, Japan, Korea, India, Australia, Indonesia, Vietnam, Turkey, Saudi Arabia, South Africa, Egypt, Brazil, Mexico, Argentina, Colombia.
Key players in global Clinical Oncology Next Generation Sequencing (NGS) market include:
Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
DNASTAR
Exosome Diagnostics
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm
Caris Life Sciences
Myriad Genetics
Market segmentation, by product types:
NGS Pre-Sequencing
Sequencing
NGS Data Analysis
Primary, Secondary & Tertiary Data Analysis
Market segmentation, by applications:
Academic & Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities
1 Industry Overview of Clinical Oncology Next Generation Sequencing (NGS)
1.1 Research Scope
1.2 Market Segmentation by Types of Clinical Oncology Next Generation Sequencing (NGS)
1.3 Market Segmentation by End Users of Clinical Oncology Next Generation Sequencing (NGS)
1.4 Market Dynamics Analysis of Clinical Oncology Next Generation Sequencing (NGS)
1.4.1 Market Drivers
1.4.2 Market Challenges
1.4.3 Market Opportunities
1.4.4 Porter’s Five Forces
2 Major Manufacturers Analysis of Clinical Oncology Next Generation Sequencing (NGS) Industry
2.1 Illumina
2.1.1 Company Overview
2.1.2 Main Products and Specifications
2.1.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.1.4 Contact Information
2.2 Roche
2.2.1 Company Overview
2.2.2 Main Products and Specifications
2.2.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.2.4 Contact Information
2.3 Agilent Technologies
2.3.1 Company Overview
2.3.2 Main Products and Specifications
2.3.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.3.4 Contact Information
2.4 Knome
2.4.1 Company Overview
2.4.2 Main Products and Specifications
2.4.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.4.4 Contact Information
2.5 Genomatix Software
2.5.1 Company Overview
2.5.2 Main Products and Specifications
2.5.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.5.4 Contact Information
2.6 GATC Biotech
2.6.1 Company Overview
2.6.2 Main Products and Specifications
2.6.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.6.4 Contact Information
2.7 Oxford Nanopore Technologies
2.7.1 Company Overview
2.7.2 Main Products and Specifications
2.7.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.7.4 Contact Information
2.8 Macrogen
2.8.1 Company Overview
2.8.2 Main Products and Specifications
2.8.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.8.4 Contact Information
2.9 Life Technologies
2.9.1 Company Overview
2.9.2 Main Products and Specifications
2.9.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.9.4 Contact Information
2.10 DNASTAR
2.10.1 Company Overview
2.10.2 Main Products and Specifications
2.10.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.10.4 Contact Information
2.11 Exosome Diagnostics
2.11.1 Company Overview
2.11.2 Main Products and Specifications
2.11.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.11.4 Contact Information
2.12 Biomatters
2.12.1 Company Overview
2.12.2 Main Products and Specifications
2.12.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.12.4 Contact Information
2.13 CLC Bio
2.13.1 Company Overview
2.13.2 Main Products and Specifications
2.13.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.13.4 Contact Information
2.14 BGI
2.14.1 Company Overview
2.14.2 Main Products and Specifications
2.14.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.14.4 Contact Information
2.15 Qiagen
2.15.1 Company Overview
2.15.2 Main Products and Specifications
2.15.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.15.4 Contact Information
2.16 Perkin Elmer
2.16.1 Company Overview
2.16.2 Main Products and Specifications
2.16.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.16.4 Contact Information
2.17 Pacific Bioscience
2.17.1 Company Overview
2.17.2 Main Products and Specifications
2.17.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.17.4 Contact Information
2.18 Partek
2.18.1 Company Overview
2.18.2 Main Products and Specifications
2.18.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.18.4 Contact Information
2.19 GnuBIO
2.19.1 Company Overview
2.19.2 Main Products and Specifications
2.19.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.19.4 Contact Information
2.20 Foundation Medicine
2.20.1 Company Overview
2.20.2 Main Products and Specifications
2.20.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.20.4 Contact Information
2.21 Paradigm
2.21.1 Company Overview
2.21.2 Main Products and Specifications
2.21.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.21.4 Contact Information
2.22 Caris Life Sciences
2.22.1 Company Overview
2.22.2 Main Products and Specifications
2.22.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.22.4 Contact Information
2.23 Myriad Genetics
2.23.1 Company Overview
2.23.2 Main Products and Specifications
2.23.3 Clinical Oncology Next Generation Sequencing (NGS) Revenue and Gross Margin (2018-2023)
2.23.4 Contact Information
3 Global Clinical Oncology Next Generation Sequencing (NGS) Market Analysis by Regions, Manufacturers, Types and End Users
3.1 Global Sales Revenue of Clinical Oncology Next Generation Sequencing (NGS) by Regions (2018-2023)
3.2 Global Sales Revenue of Clinical Oncology Next Generation Sequencing (NGS) by Manufacturers (2018-2023)
3.3 Global Sales Revenue of Clinical Oncology Next Generation Sequencing (NGS) by Types (2018-2023)
3.4 Global Sales Revenue of Clinical Oncology Next Generation Sequencing (NGS) by End Users (2018-2023)
4 Northern America Clinical Oncology Next Generation Sequencing (NGS) Market Analysis by Countries, Types and End Users
4.1 Northern America Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by Countries (2018-2023)
4.2 Northern America Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by Types (2018-2023)
4.3 Northern America Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by End Users (2018-2023)
4.4 United States Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
4.5 Canada Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
5 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Analysis by Countries, Types and End Users
5.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by Countries (2018-2023)
5.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by Types (2018-2023)
5.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by End Users (2018-2023)
5.4 Germany Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
5.5 France Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
5.6 UK Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
5.7 Italy Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
5.8 Russia Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
5.9 Spain Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
5.10 Netherlands Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
6 Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Analysis by Countries, Types and End Users
6.1 Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by Countries (2018-2023)
6.2 Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by Types (2018-2023)
6.3 Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by End Users (2018-2023)
6.4 China Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
6.5 Japan Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
6.6 Korea Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
6.7 India Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
6.8 Australia Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
6.9 Indonesia Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
6.10 Vietnam Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
7 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Analysis by Countries, Types and End Users
7.1 Latin America Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by Countries (2018-2023)
7.2 Latin America Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by Types (2018-2023)
7.3 Latin America Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by End Users (2018-2023)
7.4 Brazil Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
7.5 Mexico Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
7.6 Argentina Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
7.7 Colombia Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
8 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Analysis by Countries, Types and End Users
8.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by Countries (2018-2023)
8.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by Types (2018-2023)
8.3 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis by End Users (2018-2023)
8.4 Turkey Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
8.5 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
8.6 South Africa Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
8.7 Egypt Clinical Oncology Next Generation Sequencing (NGS) Sales Revenue Analysis (2018-2023)
9 Marketing Channel, Distributors and Traders Analysis
9.1 Marketing Channel
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 Distributors and Traders
10 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Regions, Countries, Manufacturers, Types and End Users
10.1 Global Sales Revenue Forecast of Clinical Oncology Next Generation Sequencing (NGS) by Regions (2024-2029)
10.2 Global Sales Revenue Forecast of Clinical Oncology Next Generation Sequencing (NGS) by Types (2024-2029)
10.3 Global Sales Revenue Forecast of Clinical Oncology Next Generation Sequencing (NGS) by End Users (2024-2029)
10.4 Global Revenue Forecast of Clinical Oncology Next Generation Sequencing (NGS) by Countries (2024-2029)
10.4.1 United States Revenue Forecast (2024-2029)
10.4.2 Canada Revenue Forecast (2024-2029)
10.4.3 Germany Revenue Forecast (2024-2029)
10.4.4 France Revenue Forecast (2024-2029)
10.4.5 UK Revenue Forecast (2024-2029)
10.4.6 Italy Revenue Forecast (2024-2029)
10.4.7 Russia Revenue Forecast (2024-2029)
10.4.8 Spain Revenue Forecast (2024-2029)
10.4.9 Netherlands Revenue Forecast (2024-2029)
10.4.10 China Revenue Forecast (2024-2029)
10.4.11 Japan Revenue Forecast (2024-2029)
10.4.12 Korea Revenue Forecast (2024-2029)
10.4.13 India Revenue Forecast (2024-2029)
10.4.14 Australia Revenue Forecast (2024-2029)
10.4.15 Indonesia Revenue Forecast (2024-2029)
10.4.16 Vietnam Revenue Forecast (2024-2029)
10.4.17 Brazil Revenue Forecast (2024-2029)
10.4.18 Mexico Revenue Forecast (2024-2029)
10.4.19 Argentina Revenue Forecast (2024-2029)
10.4.20 Colombia Revenue Forecast (2024-2029)
10.4.21 Turkey Revenue Forecast (2024-2029)
10.4.22 Saudi Arabia Revenue Forecast (2024-2029)
10.4.23 South Africa Revenue Forecast (2024-2029)
10.4.24 Egypt Revenue Forecast (2024-2029)
11 Industry Chain Analysis of Clinical Oncology Next Generation Sequencing (NGS)
11.1 Upstream Analysis of Clinical Oncology Next Generation Sequencing (NGS)
11.2 Downstream Major Consumers Analysis of Clinical Oncology Next Generation Sequencing (NGS)
11.3 Major Suppliers of Clinical Oncology Next Generation Sequencing (NGS) with Contact Information
11.4 Supply Chain Relationship Analysis of Clinical Oncology Next Generation Sequencing (NGS)
12 Clinical Oncology Next Generation Sequencing (NGS) New Project Investment Feasibility Analysis
12.1 Clinical Oncology Next Generation Sequencing (NGS) New Project SWOT Analysis
12.2 Clinical Oncology Next Generation Sequencing (NGS) New Project Investment Feasibility Analysis
12.2.1 Project Name
12.2.2 Investment Budget
12.2.3 Project Product Solutions
12.2.4 Project Schedule
13 Clinical Oncology Next Generation Sequencing (NGS) Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.2 References and Data Sources
14.2.1 Primary Sources
14.2.2 Secondary Paid Sources
14.2.3 Secondary Public Sources
14.3 Abbreviations and Units of Measurement
14.4 Author Details
14.5 Disclaimer
Table Types of Clinical Oncology Next Generation Sequencing (NGS)
Table End Users of Clinical Oncology Next Generation Sequencing (NGS)
Figure Market Drivers Analysis of Clinical Oncology Next Generation Sequencing (NGS)
Figure Market Challenges Analysis of Clinical Oncology Next Generation Sequencing (NGS)
Figure Market Opportunities Analysis of Clinical Oncology Next Generation Sequencing (NGS)
Table Market Drivers Analysis of Clinical Oncology Next Generation Sequencing (NGS)
Table Illumina Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Illumina
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Illumina (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Illumina (2018-2023)
Table Roche Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Roche
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Roche (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Roche (2018-2023)
Table Agilent Technologies Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Agilent Technologies
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Agilent Technologies (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Agilent Technologies (2018-2023)
Table Knome Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Knome
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Knome (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Knome (2018-2023)
Table Genomatix Software Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Genomatix Software
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Genomatix Software (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Genomatix Software (2018-2023)
Table GATC Biotech Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of GATC Biotech
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of GATC Biotech (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of GATC Biotech (2018-2023)
Table Oxford Nanopore Technologies Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Oxford Nanopore Technologies
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Oxford Nanopore Technologies (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Oxford Nanopore Technologies (2018-2023)
Table Macrogen Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Macrogen
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Macrogen (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Macrogen (2018-2023)
Table Life Technologies Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Life Technologies
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Life Technologies (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Life Technologies (2018-2023)
Table DNASTAR Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of DNASTAR
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of DNASTAR (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of DNASTAR (2018-2023)
Table Exosome Diagnostics Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Exosome Diagnostics
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Exosome Diagnostics (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Exosome Diagnostics (2018-2023)
Table Biomatters Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Biomatters
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Biomatters (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Biomatters (2018-2023)
Table CLC Bio Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of CLC Bio
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of CLC Bio (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of CLC Bio (2018-2023)
Table BGI Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of BGI
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of BGI (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of BGI (2018-2023)
Table Qiagen Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Qiagen
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Qiagen (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Qiagen (2018-2023)
Table Perkin Elmer Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Perkin Elmer
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Perkin Elmer (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Perkin Elmer (2018-2023)
Table Pacific Bioscience Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Pacific Bioscience
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Pacific Bioscience (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Pacific Bioscience (2018-2023)
Table Partek Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Partek
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Partek (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Partek (2018-2023)
Table GnuBIO Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of GnuBIO
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of GnuBIO (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of GnuBIO (2018-2023)
Table Foundation Medicine Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Foundation Medicine
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Foundation Medicine (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Foundation Medicine (2018-2023)
Table Paradigm Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Paradigm
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Paradigm (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Paradigm (2018-2023)
Table Caris Life Sciences Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Caris Life Sciences
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Caris Life Sciences (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Caris Life Sciences (2018-2023)
Table Myriad Genetics Information List
Figure Clinical Oncology Next Generation Sequencing (NGS) Specifications of Myriad Genetics
Table Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Gross Margin of Myriad Genetics (2018-2023)
Figure Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Global Market Share of Myriad Genetics (2018-2023)
Table Global Revenue (Million USD) of Clinical Oncology Next Generation Sequencing (NGS) by Regions (2018-2023)
Table Global Revenue (Million USD) of Clinical Oncology Next Generation Sequencing (NGS) by Manufacturers (2018-2023)
Table Global Revenue (Million USD) of Clinical Oncology Next Generation Sequencing (NGS) by Types (2018-2023)
Table Global Revenue (Million USD) of Clinical Oncology Next Generation Sequencing (NGS) by End Users (2018-2023)
Table Northern America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2018-2023)
Table Northern America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Types (2018-2023)
Table Northern America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by End Users (2018-2023)
Figure United States Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Canada Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Table Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2018-2023)
Table Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Types (2018-2023)
Table Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by End Users (2018-2023)
Figure Germany Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure France Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure UK Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Italy Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Russia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Spain Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Netherlands Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Table Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2018-2023)
Table Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Types (2018-2023)
Table Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by End Users (2018-2023)
Figure China Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Japan Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Korea Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure India Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Australia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Indonesia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Vietnam Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Table Latin America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2018-2023)
Table Latin America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Types (2018-2023)
Table Latin America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by End Users (2018-2023)
Figure Brazil Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Mexico Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Argentina Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Colombia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Table Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2018-2023)
Table Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Types (2018-2023)
Table Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by End Users (2018-2023)
Figure Turkey Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure South Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Figure Egypt Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2018-2023)
Table Global Revenue (Million USD) Forecast of Clinical Oncology Next Generation Sequencing (NGS) by Regions (2024-2029)
Table Global Revenue (Million USD) Forecast of Clinical Oncology Next Generation Sequencing (NGS) by Types (2024-2029)
Table Global Revenue (Million USD) Forecast of Clinical Oncology Next Generation Sequencing (NGS) by End Users (2024-2029)
Table Major Consumers with Contact Information of Clinical Oncology Next Generation Sequencing (NGS)
Table Major Suppliers of Clinical Oncology Next Generation Sequencing (NGS) with Contact Information
Figure Supply Chain Relationship Analysis of Clinical Oncology Next Generation Sequencing (NGS)
Table New Project SWOT Analysis of Clinical Oncology Next Generation Sequencing (NGS)
Table Project Appraisal and Financing
Table New Project Construction Period
Table New Project Investment Feasibility Analysis of Clinical Oncology Next Generation Sequencing (NGS)
Table Research Programs/Design for This Report
Table Key Data Information from Primary Sources
Table Key Data Information from Secondary Sources
Table Part of Interviewees Record List of Clinical Oncology Next Generation Sequencing (NGS) Industry
Table Part of References List of Clinical Oncology Next Generation Sequencing (NGS) Industry
Table Units of Measurement List
Table Part of Author Details List of Clinical Oncology Next Generation Sequencing (NGS) Industry
HJ Research employs comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecast possible. At HJ Research, our researchers and domain experts use a unique blend of primary and secondary research, with validation and iterations at every stage, in order to minimize deviation and present the most accurate analysis of the Clinical Oncology Next Generation Sequencing (NGS) industry. Critical elements of methodology employed for all our studies include:
Secondary Sources:
The research team first works with national bureau of statistics, national customs, market research association, state information center, and administration that operate in the research field. The information provided by our in-house documentation service helps us carrying out further research. Secondary sources are mainly from press releases, company reports and publications, non-profit organizations, industry associations, government publications, economic and demographic data and customs data. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. Our team which has the experience as well as the knowledge efficiently extracts the accurate information from existing source.
Primary Research:
In the primary research process, for comprehensive understanding of the Clinical Oncology Next Generation Sequencing (NGS) market, it is essential to understand the complete value chain and in order to facilitate this, we collect data from Clinical Oncology Next Generation Sequencing (NGS) manufacturers, Clinical Oncology Next Generation Sequencing (NGS) raw material suppliers, Clinical Oncology Next Generation Sequencing (NGS) distributors as well as buyers. The primary sources from the supply side include Clinical Oncology Next Generation Sequencing (NGS) manufacturers, opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the Clinical Oncology Next Generation Sequencing (NGS) raw materials suppliers and producers, etc. The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users, and related key executives from various key companies and organizations operating in the global market.
Technical issues and trends are obtained from surveys, technical symposia and trade journals. Technical data is also gathered from intellectual property perspective, focusing on white space and freedom of movement. Industry dynamics with respect to drivers, restraints, pricing trends are also gathered.
Statistical Model and Data Analysis:
Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development and pricing trends is fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, and industry experience and domain expertise. Qualitative analysis includes: Clinical Oncology Next Generation Sequencing (NGS) industry landscape and trends, Clinical Oncology Next Generation Sequencing (NGS) market dynamics and key issues, Clinical Oncology Next Generation Sequencing (NGS) technology landscape, market opportunities, porter’s analysis and PESTEL analysis, Clinical Oncology Next Generation Sequencing (NGS) competitive landscape and component benchmarking, policy and regulatory scenario. Quantitative analysis includes: Clinical Oncology Next Generation Sequencing (NGS) market size and forecast by regions, Clinical Oncology Next Generation Sequencing (NGS) market size and forecast by application, Clinical Oncology Next Generation Sequencing (NGS) market size and forecast by types, Clinical Oncology Next Generation Sequencing (NGS) company market share etc.
Quality Control:
Before publishing, every report goes under a rigorous checking and editing process, which is done by experience management team to ensure the reliability of the published data. Each analyst in the research team receives support and on-going training which is part of the HJ Research’s internal quality process.
